Values First Advisors Inc. Has $348,000 Stock Position in Neogen Co. (NASDAQ:NEOG)

Values First Advisors Inc. grew its stake in Neogen Co. (NASDAQ:NEOG) by 77.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,692 shares of the company’s stock after buying an additional 12,545 shares during the quarter. Values First Advisors Inc.’s holdings in Neogen were worth $348,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Conestoga Capital Advisors LLC lifted its position in Neogen by 24.5% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 8,706,224 shares of the company’s stock valued at $146,352,000 after acquiring an additional 1,711,238 shares in the last quarter. State Street Corp lifted its holdings in shares of Neogen by 3.1% in the third quarter. State Street Corp now owns 7,932,192 shares of the company’s stock valued at $133,340,000 after purchasing an additional 236,762 shares in the last quarter. Bamco Inc. NY lifted its holdings in shares of Neogen by 1.4% in the third quarter. Bamco Inc. NY now owns 7,303,115 shares of the company’s stock valued at $122,765,000 after purchasing an additional 98,067 shares in the last quarter. Champlain Investment Partners LLC boosted its position in shares of Neogen by 10.7% during the third quarter. Champlain Investment Partners LLC now owns 7,110,530 shares of the company’s stock worth $119,528,000 after buying an additional 690,029 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Neogen by 0.4% during the third quarter. Geode Capital Management LLC now owns 5,148,388 shares of the company’s stock worth $86,559,000 after buying an additional 20,387 shares in the last quarter. Institutional investors own 96.73% of the company’s stock.

Insider Buying and Selling

In other news, CEO John Edward Adent acquired 23,035 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was bought at an average price of $11.03 per share, with a total value of $254,076.05. Following the transaction, the chief executive officer now directly owns 269,164 shares in the company, valued at approximately $2,968,878.92. The trade was a 9.36 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO David H. Naemura bought 14,800 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was purchased at an average cost of $11.11 per share, for a total transaction of $164,428.00. Following the completion of the acquisition, the chief financial officer now owns 61,434 shares in the company, valued at $682,531.74. This trade represents a 31.74 % increase in their position. The disclosure for this purchase can be found here. 1.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have commented on NEOG. Guggenheim began coverage on Neogen in a research note on Thursday, December 19th. They issued a “buy” rating and a $15.00 target price on the stock. Piper Sandler reissued a “neutral” rating and issued a $13.00 price objective (down previously from $16.50) on shares of Neogen in a research report on Tuesday, January 21st.

Neogen Trading Down 2.1 %

Shares of NASDAQ NEOG opened at $9.95 on Thursday. Neogen Co. has a fifty-two week low of $9.94 and a fifty-two week high of $18.58. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.46 and a current ratio of 3.77. The business has a 50-day moving average of $11.89 and a 200-day moving average of $14.29.

Neogen (NASDAQ:NEOG) last posted its quarterly earnings results on Friday, January 10th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.12. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The firm had revenue of $231.30 million during the quarter, compared to the consensus estimate of $227.16 million. During the same period last year, the company earned $0.11 earnings per share. The business’s revenue was up .7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Neogen Co. will post 0.38 EPS for the current fiscal year.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.